Ftse Mib
33.832,61
0,60%
DAX
18.071,30
0,43%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
65.187,80
1,86%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. USOTC Amarantus Bioscience Holdings Inc (CE) (AMBS) Amarantus Bioscience Holdings Inc (CE) (AMBS) Notizie

AMBS

Amarantus Bioscience (CE) (AMBS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:USOTC:AMBS
DataOraFonteTitoloSimboloCompagnia
09/09/202220:20Edgar (US Regulatory)Sec Staff Action/letter (sec Staff)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
18/04/202222:18Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
09/10/202012:02Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
10/07/202021:03InvestorsHub NewsWireTodos Medical Expands Extraction Reagent and ANDiS 350 Extraction Automation Capacity to Support COVID-19 Testing in the USAUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
30/01/202015:42InvestorsHub NewsWireAmarantus Acquires Majority Interest in CBD Wellness Company HemporiUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
10/01/202012:52Edgar (US Regulatory)Withdrawal of Offering Statement Under Regulation a (1-a-w)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
09/01/202023:13Edgar (US Regulatory)Amended Registration a Offering Under the Securities Act of 1933 (1-a/a)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
09/01/202023:06Edgar (US Regulatory)Registration a Offering Under the Securities Act of 1933 (1-a)USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
04/12/201914:17InvestorsHub NewsWireAmarantus Sub Elto Pharma Gets Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson's DiseaseUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
24/10/201915:52InvestorsHub NewsWireAmarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic ProductsUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
28/05/201915:51InvestorsHub NewsWireAmarantus Engages Evolution Venture Partners to Evaluate Strategic Alternatives for Expansion into the Legal Hemp IndustryUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
07/01/201914:00InvestorsHub NewsWireAmarantus Provides 2019 RoadmapUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
28/11/201813:30InvestorsHub NewsWireCoeptis Pharma Enters into Agreement to Acquire Elto PharmaUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
20/07/201813:31InvestorsHub NewsWireAmarantus Provides Corporate UpdateUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
09/07/201814:00InvestorsHub NewsWireMANF Therapeutics Announces Positive MANF Pre-Clinical Data in Alpha-Synuclein Model of Parkinson's Disease Published inUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
11/06/201813:00InvestorsHub NewsWireMANF Therapeutics Announces Independent Publication of Positive Data for MANF in Traumatic Brain Injury Animal ModelUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
07/06/201814:17InvestorsHub NewsWireAmarantus Provides Update on Elto Pharma Capital Formation PlanUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
05/06/201814:11InvestorsHub NewsWireMANF Therapeutics Announces Publication of Positive Data for MANF in Stroke Animal Model in AAAS Journal Science AdvancesUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
30/05/201814:00InvestorsHub NewsWireAmarantus Exercises Exclusive Option with Leipzig University for Alzheimer's Blood Diagnostic "LymPro Test 2.0"USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
24/05/201817:00InvestorsHub NewsWireAmarantus to Present at LD Micro and The Reg A ConferenceUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
22/05/201812:00InvestorsHub NewsWireAmarantus Retains Weild & Co. to Advise on JOBS Act FundingUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
21/05/201813:58InvestorsHub NewsWireMANF Therapeutics Announces Publication in Society for Neuroscience eNeuro Journal of Human Ocular Distribution and Animal..USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
11/05/201813:00InvestorsHub NewsWireAmarantus Provides Business OverviewUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
04/05/201814:16InvestorsHub NewsWireAmarantus Enters into Exclusive Option Agreement with Leipzig University to License IP Covering Alzheimer's Blood DiagnosticUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
03/05/201815:15InvestorsHub NewsWireMANF Therapeutics Announces Issuance of Patent in Hong Kong Covering Use of MANF for Treatment of Diabetes and Wolfram's NewUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
01/05/201816:30InvestorsHub NewsWireElto Pharma Receives Notice of Allowance in Canada for Patent Covering Use of Eltoprazine to Treat non-ADHD Cognitive Impairm...USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
30/04/201813:00InvestorsHub NewsWireElto Pharma Appoints Paula Trzepacz, MD as Chief Medical Advisor Ex-Lilly Sr. Medical Fellow in Neurosciences to leadUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
23/04/201814:00InvestorsHub NewsWireCutanogen Appoints Richard Kagan, MD as Chief Medical Advisor Emeritus Chief of Staff of Shriners Burns Hospital - Cincinnati...USOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
16/04/201813:30InvestorsHub NewsWireAmarantus Appoints Michael T. Ropacki, PhD as Chief Medical Advisor for Alzheimer's Blood Diagnostic LymPro Test ProgramUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
09/04/201818:40InvestorsHub NewsWireAmarantus to Present at The Microcap Conference in NYCUSOTC:AMBSAmarantus Bioscience Holdings Inc (CE)
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:USOTC:AMBS

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STLAM
Stellantis NV
BIT
UCG
Unicredit
BIT
ENEL
Enel
BIT
SPM
Saipem
BIT
BAMI
Banco BPM
BIT
ENI
Eni
BIT
BPE
Bper Banca
BIT
RACE
Ferrari NV
BIT
TIT
Telecom Italia
BIT
LDO
Leonardo
BIT
STMMI
ST Microelectronics
BIT
NEXI
Nexi S.p.A
BIT
A2A
A2A
BIT
TEN
Tenaris
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network